Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.
Fisher G, Pommier R, Wolin E, Kunz P, Liyanage N, Pitman Lowenthal S, Mirakhur B, Shaheen M, Vinik A. Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Journal Of Clinical Oncology 2017, 35: 4088-4088. DOI: 10.1200/jco.2017.35.15_suppl.4088.Peer-Reviewed Original ResearchLanreotide depotCarcinoid syndromeSymptomatic controlOCT useInteractive voice/web response systemPatient-reported symptomsWeb response systemNeuroendocrine tumor patientsSeverity of symptomsPercentage of daysPlasma chromograninRescue therapyNET patientsWeek 12Severe diarrheaTumor patientsCgA levelsLAN treatmentNaive groupCS symptomsWk 12Symptom dataPlaceboMean differenceSymptoms